Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 158Pancreatic Neoplasms 148Carcinoma, Hepatocellular 127Colonic Neoplasms 79Stomach Neoplasms 58Rectal Neoplasms 58Liver Neoplasms 47Esophageal Neoplasms 46Breast Neoplasms 40Neoplasms 36Neoplasm Metastasis 35Cholangiocarcinoma 32Lung Neoplasms 23Gastrointestinal Neoplasms 20Ovarian Neoplasms 17Biliary Tract Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Esophageal Squamous Cell Carcinoma 13Uterine Cervical Neoplasms 11Gallbladder Neoplasms 10Adenocarcinoma 10Sarcoma 9Carcinoma, Renal Cell 9Adenocarcinoma Of Esophagus 9Urinary Bladder Neoplasms 8Recurrence 8Bile Duct Neoplasms 8Prostatic Neoplasms 7Gastrointestinal Stromal Tumors 7Colonic Polyps 7

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Camurati-Engelmann Syndrome × Gastrointestinal × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡